Pharmaceutical

VSee Health, Inc. Announces Postponement of Annual Meeting of Stockholders Until December 30, 2025

SAN JOSE, CALIFORNIA / ACCESS Newswire / December 12, 2025 / VSee Health, Inc. (NASDAQ:VSEE) a leader in innovative telemedicine…

2 weeks ago

BoomRx Debuts Single Portal for Prescription Sourcing and Fulfillment

New Technology Platform Reduces Administrative Burden for Healthcare Providers NationwideTAMPA, Fla., Dec. 12, 2025 /PRNewswire/ -- BoomRx, a fast-growing national…

2 weeks ago

Global Attention: POGMENT Biomimetic Collagen “Stable Triple-Helix Breakthrough” –Unconventional and Astonishing

— LivingPhoenix Forum's 12 Conference Presentation Ignite International and Domestic Academia, Hailed by Academicians as the "iPhone Moment for Extracellular…

2 weeks ago

Cadrenal’s Quiet Expansion Play Is Starting to Get Loud

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) entered the back half of the…

2 weeks ago

Cadrenal’s Anticoagulation Platform Is Expanding in a $40 Billion Market

PONTE VEDRA, FL / ACCESS Newswire / December 12, 2025 / Cadrenal Therapeutics (NASDAQ:CVKD) believes it continues to be misread…

2 weeks ago

VSee Health, Inc. Regains Compliance with Nasdaq Stockholders’ Equity Requirement

SAN JOSE, CALIFORNIA / ACCESS Newswire / December 12, 2025 / VSee Health, Inc. (Nasdaq:VSEE, VSEEW), a leading provider of…

2 weeks ago

Parexel Named “Best Contract Research Organization” at 21st Annual Scrip Awards

Industry leader recognized for excellence and innovation in clinical developmentRALEIGH, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Parexel, a leading…

2 weeks ago

Additional Confirmed Response Reported as Part of Amplia Investor Presentation

HIGHLIGHTS An additional confirmed partial response has been recorded in the ongoing ACCENT trialThis brings the confirmed Objective Response Rate…

2 weeks ago

Cytokinetics Announces Positive CHMP Opinion of MYQORZO® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics,…

2 weeks ago

Clearmind Medicine’s MEAI Spotlighted in Prestigious Review: Leading Experts Affirm Transformative Potential for Alcohol Use Disorder Treatment

Vancouver, Canada, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

2 weeks ago